Xenin-25 amplifies GIP-mediated insulin secretion in humans with normal and impaired glucose tolerance but not type 2 diabetes

Diabetes

Volumn 61, Issue 7, 2012, Pages 1793-1800

  Wice, Burton M ^a   Reeds, Dominic N ^a   Tran, Hung D ^a   Crimmins, Dan L ^a   Patterson, Bruce W ^a   Dunai, Judit ^a   Wallendorf, Michael J ^a   Ladenson, Jack H ^a   Villareal, Dennis T ^a,b   Polonsky, Kenneth S ^a,c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCOSE; INSULIN; NEUROTENSIN DERIVATIVE; UNCLASSIFIED DRUG; XENIN 25;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DIET RESTRICTION; FEMALE; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE INFUSION; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RELEASE; LOOSE FECES; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

ADULT; BLOOD GLUCOSE; C-PEPTIDE; DIABETES MELLITUS, TYPE 2; FEMALE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCOSE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; MALE; MIDDLE AGED; NEUROTENSIN;

EID: 84863207816     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db11-1451     Document Type: Article

References (37)

1. Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 2009;5:262-269
2. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007;132:2131-2157 (Pubitemid 46711096)
3. Brand SJ, Schmidt WE. Gastrointestinal hormones. In Textbook of Gastroenterology. 2nd ed. Yamada T, Ed. Philadelphia, JB Lippincott Company, 1995, p. 25-71
4. Walsh JH. Gastrointestinal hormones. In Physiology of the Gastrointestinal Tract. 3rd ed. Johnson LR, Ed. New York, Raven Press, 1994, p. 1-128
5. Fehmann HC, Göke R, Göke B. Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide. Endocr Rev 1995;16:390-410
6. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993;91:301-307 (Pubitemid 23037285)
7. Elahi D, McAloon-Dyke M, Fukagawa NK, et al. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regul Pept 1994;51:63-74 (Pubitemid 24119981)
8. Vilsbøll T, Krarup T, Madsbad S, Holst JJ. Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients. Diabetologia 2002;45:1111-1119 (Pubitemid 34985287)
9. Althage MC, Ford EL, Wang S, Tso P, Polonsky KS, Wice BM. Targeted ablation of glucose-dependent insulinotropic polypeptide-producing cells in transgenic mice reduces obesity and insulin resistance induced by a high fat diet. J Biol Chem 2008;283:18365-18376
10. Wice BM, Wang S, Crimmins DL, et al. Xenin-25 potentiates glucose-dependent insulinotropic polypeptide action via a novel cholinergic relay mechanism. J Biol Chem 2010;285:19842-19853
11. Feurle GE. Xenin - a review. Peptides 1998;19:609-615 (Pubitemid 28161176)
12. Anlauf M, Weihe E, Hartschuh W, Hamscher G, Feurle GE. Localization of xenin-immunoreactive cells in the duodenal mucosa of humans and various mammals. J Histochem Cytochem 2000;48:1617-1626
13. Leiter EH, Reifsnyder PC. Differential levels of diabetogenic stress in two newmouse models of obesity and type 2 diabetes. Diabetes 2004;53(Suppl. 1):S4-S11 (Pubitemid 38168686)
14. Reifsnyder PC, Leiter EH. Deconstructing and reconstructing obesity-induced diabetes (diabesity) in mice. Diabetes 2002;51:825-832 (Pubitemid 34760196)
15. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-1197
16. McGuire EA, Helderman JH, Tobin JD, Andres R, Berman M. Effects of arterial versus venous sampling on analysis of glucose kinetics in man. J Appl Physiol 1976;41:565-573
17. Brooks DC, Black PR, Arcangeli MA, Aoki TT, Wilmore DW. The heated dorsal hand vein: an alternative arterial sampling site. JPEN J Parenter Enteral Nutr 1989;13:102-105 (Pubitemid 19041673)
18. Feurle GE, Pfeiffer A, Schmidt T, Dominguez-Munoz E, Malfertheiner P, Hamscher G. Phase III of the migrating motor complex: associated with endogenous xenin plasma peaks and induced by exogenous xenin. Neurogastroenterol Motil 2001;13:237-246 (Pubitemid 32525675)
19. Van Cauter E, Mestrez F, Sturis J, Polonsky KS. Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 1992;41:368-377
20. Sparacino G, Cobelli C. A stochastic deconvolution method to reconstruct insulin secretion rate after a glucose stimulus. IEEE Trans Biomed Eng 1996;43:512-529 (Pubitemid 26131473)
21. Sparacino G, Pillonetto G, Capello M, De Nicolao G, Cobelli C. WINSTODEC: a stochastic deconvolution interactive program for physiological and pharmacokinetic systems. Comput Methods Programs Biomed 2002;67:67-77 (Pubitemid 34031726)
22. Nustede R, Schmidt WE, Horstmann O, Sikovec N, Schemminger R, Becker H. On the effect of xenin and xenin fragments on exocrine pancreas secretion in vivo. Regul Pept 1999;81:61-66 (Pubitemid 29248801)
23. Kim ER, Mizuno TM. Role of neurotensin receptor 1 in the regulation of food intake by neuromedins and neuromedin-related peptides. Neurosci Lett 2010;468:64-67
24. Feurle GE, Klein A, Hamscher G, Metzger JW, Schuurkes JA. Neurokinetic and myokinetic effects of the peptide xenin on the motility of the small and large intestine of guinea pig. J Pharmacol Exp Ther 1996;278:654-661 (Pubitemid 27167031)
25. Feurle GE, Metzger JW, Grudinki A, Hamscher G. Interaction of xenin with the neurotensin receptor of guinea pig enteral smooth muscles. Peptides 2002;23:1519-1525 (Pubitemid 35223023)
26. Clemens A, Katsoulis S, Nustede R, et al. Relaxant effect of xenin on rat ileum is mediated by apamin-sensitive neurotensin-type receptors. Am J Physiol 1997;272:G190-G196
27. Pettibone DJ, Hess JF, Hey PJ, et al. The effects of deleting the mouse neurotensin receptor NTR1 on central and peripheral responses to neurotensin. J Pharmacol Exp Ther 2002;300:305-313 (Pubitemid 34028541)
28. Blackburn AM, Fletcher DR, Adrian TE, Bloom SR. Neurotensin infusion in man: pharmacokinetics and effect on gastrointestinal and pituitary hormones. J Clin Endocrinol Metab 1980;51:1257-1261 (Pubitemid 11199609)
29. Meier JJ, Gallwitz B, Kask B, et al. Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects. Diabetes 2004;53(Suppl. 3):S220-S224 (Pubitemid 39564547)
30. Meier JJ, Nauck MA, Siepmann N, et al. Similar insulin secretory response to a gastric inhibitory polypeptide bolus injection at euglycemia in firstdegree relatives of patients with type 2 diabetes and control subjects. Metabolism 2003;52:1579-1585 (Pubitemid 38049275)
31. Meier JJ, Nauck MA. Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function? Diabetes 2010;59:1117-1125
32. Ahrén B, Holst JJ. The cephalic insulin response to meal ingestion in humans is dependent on both cholinergic and noncholinergic mechanisms and is important for postprandial glycemia. Diabetes 2001;50:1030-1038 (Pubitemid 32374533)
33. Meier JJ, Gallwitz B, Siepmann N, et al. Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia 2003;46:798-801 (Pubitemid 36831408)
34. Elahi D, Andersen DK, Brown JC, et al. Pancreatic alpha- and beta-cell responses to GIP infusion in normal man. Am J Physiol 1979;237:E185-E191 (Pubitemid 9240781)
35. Young A. Inhibition of glucagon secretion. Adv Pharmacol 2005;52:151-171 (Pubitemid 43631254)
36. Duttaroy A, Zimliki CL, Gautam D, Cui Y, Mears D, Wess J. Muscarinic stimulation of pancreatic insulin and glucagon release is abolished in m3 muscarinic acetylcholine receptor-deficient mice. Diabetes 2004;53:1714-1720 (Pubitemid 38857029)
37. Feurle GE, Ikonomu S, Partoulas G, Stoschus B, Hamscher G. Xenin plasma concentrations during modified sham feeding and during meals of different composition demonstrated by radioimmunoassay and chromatography. Regul Pept 2003;111:153-159 (Pubitemid 36254763)